Join the Movement to Build a Century-Defining Technology

Synthetic biology isn’t a household name – yet. But it will be soon, because it’s a thriving, innovative field that’s solving some of humanity’s greatest and most pressing challenges…
Antheia to access Ginkgo’s enzyme screening and design technology

Ginkgo Bioworks, a Boston-based cell-programming specialist, will deploy its high-throughput enzyme design and screening technology to help the synthetic biology firm Antheia broaden its pipeline of drug active ingredients…
Brewing up plant-inspired medicines

Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs…
On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm

California synthetic biology firm Antheia has joined forces with Boston-based biotech company Ginkgo Bioworks to strengthen its efforts to develop and produce essential medicines to treat a wide range of diseases…
Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines using Synthetic Biology

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development…
Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology…

With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy, synthetic biology upstart Antheia…
Biomanufacturing draws hundreds of millions in investments

Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…
Antheia Raises $73M in Series B

Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire…
Antheia Secures $73M in Series B

Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B funding…
Antheia raises $73 million for drugs from reprogrammed yeast

Antheia, a synthetic biology company cofounded and led by Stanford University bioengineer Christina Smolke, has raised $73 million in series B financing…